Interstitial lung disease: Current concepts of pathogenesis, staging and therapy

Crystal, Ronald G.; Gadek, James E.; Ferrans, Víctor J.; Fulmer, Jack D.; Line, Bruce R.; Hunninghake, Gary W.

doi:10.1016/0002-9343(81)90577-5

Cited by 505 publications

(199 citation statements)

References 141 publications

Supporting

Mentioning

186

Contrasting

Unclassified

Order By: Relevance

“…Although the term "idiopathJc' suggests that IPF may be a collection of fibrotic disorders of unknown aetiology. IPF is believed to be a specific disorder with characteristic features [18,19]. IPF usually begins in middle age presenting with dyspnoea with exercise, and has a 4-5 year course from onset to death.…”

Section: Discussionmentioning

confidence: 99%

Circulating intercellular adhesion molecule-1 (ICAM-1) antigen in sera of patients with idiopathic pulmonary fibrosis

Shijubo

Imai

Aoki

et al. 1992

Clinical and Experimental Immunology

View full text Add to dashboard Cite

SUMMARY Intercellular adhesion molecule‐1 (ICAM‐1), a member of immunoglobulin supergene family with a five‐domain structure, is known to play an important role in inflammatory diseases. An ELISA was developed using two MoAbs against human ICAM‐1 in order to detect the soluble shedding ICAM‐1 antigen in sera. We measured levels of circulating ICAM‐1 antigen in sera of patients with idiopathic pulmonary fibrosis (IPF), pulmonary sarcoidosis, hypersensitive pneumonitis, bacterial and mycoplasmal pneumonia, and inflammatory diseases of other organs. The results clearly demonstrated that IPF had significantly high levels of circulating ICAM‐1 in sera as compared with other disorders or normal controls. Moreover, immunohistochemical analysis with MoAb against human ICAM‐1 disclosed that in IPF, the expression of ICAM‐1 was intensively enhanced on alveolar epithelial cells. These results suggest that ICAM‐1 may contribute to the pathogenesis of IPF.

show abstract

Section: Discussionmentioning

confidence: 99%

Circulating intercellular adhesion molecule-1 (ICAM-1) antigen in sera of patients with idiopathic pulmonary fibrosis

Shijubo

Imai

Aoki

et al. 1992

Clinical and Experimental Immunology

View full text Add to dashboard Cite

show abstract

“…Patients with PM-DM were divided into 2 groups based on the presence or absence of antibodies to the Jo-1 antigen, and clinical characteristics were compared between the groups. Presence of pulmonary fibrosis was determined by chest roentgenogram, and its severity was graded according to Crystal et a1 (19,20). The statistical analysis was performed by the Student's 1-test.…”

Section: (18)mentioning

confidence: 99%

The Precipitating Antibody to an Acidic Nuclear Protein Antigen, the Jo‐1, in Connective Tissue Diseases

Yoshida

Akizuki

Mimori

et al. 1983

Arthritis & Rheumatism

218

View full text Add to dashboard Cite

A Marker for a Subset of Polymyositis with Interstitial Pulmonary Fibrosis SHUNJI YOSHIDA, MASASHI AKIZUKI, TSUNEYO MIMORI, HAJIME YAMAGATA, SHINICHI INADA, and MITSUO HOMMAThe clinical significance of antibodies to the Jo-1 antigen in connective tissue diseases was studied. Clinical diagnoses of I1 patients who had anti-Jo-1 antibody were: polymyositis 8, dermatomyositis 1, and overlap syndrome 2 (polymyositis-systemic lupus erythematosus 1, polymyositis-scleroderma 1). All the patients who had anti-Jo-1 antibody showed interstitial pulmonary fibrosis, and in 2 patients antiJo-1 antibodies were detected before the appearance of lung disease.Identification of antinuclear antibodies with defined specificities has diagnostic and prognostic value in connective tissue diseases (1-3). Recent studies reveal the presence of several precipitating antibody systems in polymyositis-dermatomyositis (PM-DM) in which immunologic abnormalities were previously considered to be infrequent (4-8). However, the results from several laboratories indicate that these serologic reactions have considerable heterogeneity, and their mutual relationships and clinical significance remain to be clarified (8).We have reported two distinct precipitating

show abstract

“…Lung biopsy is necessary for specific diagnosis. 2,3,16 Favorable response to steroids has been reported in young patients given the drug early in the course of the disease. Females are reported to respond better than males.…”

Section: Discussionmentioning

confidence: 99%

“…9 Other drugs have also been used. 3 Idiopathic pulmonary fibrosis was first described in children by Bradley in 1956. 17 Single reports followed thereafter.…”

Section: Discussionmentioning

confidence: 99%

“…2 The cell count of bronchoalveolar lavage does add to the diagnosis of the specific clinical entities of the interstitial lung diseases and helps to monitor response to therapy on follow-up. 3 The gallium-67 scan is used to monitor the response to therapy as it detects the extent and intensity of effector cells accumulation and activation in the lung. 3 The insidious onset, the symptoms, the clinical features, investigations, and response to treatment in these two children are similar to what has hitherto been described in patients with idiopathic pulmonary fibrosis.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Idiopathic Pulmonary Fibrosis in Two Saudi Children

Adam

1988

Ann Saudi Med

View full text Add to dashboard Cite

Interstitial lung disease: Current concepts of pathogenesis, staging and therapy

Cited by 505 publications

References 141 publications

Circulating intercellular adhesion molecule-1 (ICAM-1) antigen in sera of patients with idiopathic pulmonary fibrosis

Circulating intercellular adhesion molecule-1 (ICAM-1) antigen in sera of patients with idiopathic pulmonary fibrosis

The Precipitating Antibody to an Acidic Nuclear Protein Antigen, the Jo‐1, in Connective Tissue Diseases

Idiopathic Pulmonary Fibrosis in Two Saudi Children

Contact Info

Product

Resources

About